Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00185042 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

A Phase 2 study of Coronary Heart Disease, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 2
Development phase
534
Enrollment target
20
Study locations

NCT00185042 is a Phase 2 study of Coronary Heart Disease that has completed, run by Daiichi Sankyo. The registered enrollment target is 534 participants, below the 1,460-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00185042, a Phase 2 study of Coronary Heart Disease, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 2
Development phase
534 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to learn if CS-505 is safe and effective for slowing down or possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood vessels of the heart (coronary artery atherosclerosis).

Conditions Studied

Coronary Heart Disease

Interventions

  • DRUG Pactimibe, CS-505

Study Locations (20)

Florida

  • - Clearwater
  • - Gainsville
  • - Hudson
  • - Jacksonville
  • - Melbourne
  • - Miami
  • - Pensacola
  • - Port Charlotte
  • - Sarasota
  • - Tallahassee
  • - Tampa

Alabama

  • - Birmingham
  • - Huntsville
  • - Mobile

California

  • - Los Angeles
  • - San Diego

Arizona

  • - Phoenix

Colorado

  • - Fort Collins

Connecticut

  • - Bridgeport

Delaware

  • - Newark

Trial Details

FieldValue
Enrollment Target 534 participants
Start Date 2002-11
Est. Completion 2005-07
Phase Phase 2

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00185042

The ClinicalTrials.gov registry entry for NCT00185042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 534 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,460-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (63% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Pactimibe, CS-505 is the first listed.

NCT00185042 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT00185042 about?

NCT00185042 is a clinical study titled "Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease". The purpose of this study is to learn if CS-505 is safe and effective for slowing down or possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood vessels of the heart (coronary artery atherosclerosis).

What is the current status of trial NCT00185042?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 534 participants. The study started on 2002-11. Estimated completion is 2005-07.

What conditions does trial NCT00185042 study?

This clinical trial studies the following conditions: Coronary Heart Disease.

What interventions are being tested in trial NCT00185042?

The interventions under investigation include: Pactimibe, CS-505 (DRUG).

Who is sponsoring clinical trial NCT00185042?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00185042 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Heart Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.